Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Digital RESI June IPC Winners

16 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

At Digital RESI June, nearly 50 life science and healthcare startups participated in the Innovator’s Pitch Challenge (IPC), a unique pitching opportunity for early-stage companies in therapeutics, medical device, diagnostics, digital health, and R&D/services sectors.

All attendees are encouraged to participate in viewing each finalist’s dedicated webpage, pitching materials, and live session in order to vote for the best pitch at RESI. Everyone from fellow startup founders to active early-stage investors votes for their favorite companies based on the materials displayed on their dedicated landing pages (pitch video, slide deck, executive summary, etc.) as well as their performance in live Q&A sessions, in which founders pitch directly to and participate in a subsequent Q&A with investor judges.

Life Science Nation is pleased to share the winners of last week’s IPC who received the most votes during the 3-day conference. Congratulations to the winners! Check them out below and see the full list of finalists. The IPC returns to an in-person format September 21-22 at RESI Boston! Contact us to learn more and apply.

Surgical Automations, Inc. – First Place
We are building the Tesla for endoscopic procedures. We are developing Automated Endoscopic Robots for procedures such as Upper and Lower GI endoscopy, Cystoscopy and Ureteroscopy, Endotracheal Intubation and Bronchoscopy. Our core technology is AI based Automated Robotic Endoluminal Navigation (AREN) and is supplemented by an IoT infrastructure that enables us to offer an integrated stakeholder experience to patients, physicians and the hospital leadership. The automated scanning of the anatomy is performed in a predetermined fashion ensuring all areas are visualized. During scanning, our AI/ML algorithms that are developed after extensive training on the images, identify the target anatomy and screen for any visual abnormality. If identified and when indicated, the robot will recommend the procedure to perform. Upon confirmation from the physician, the robot will mark a trajectory on the lesion predicting the exact location where the intervention will be done. Upon confirmation from the physician, the robot will perform the procedure. All this is automated and done under the supervision of the physician who has the capability to manually override at any time. Additionally, in addition to providing us with important data for business analytics, the IoT infrastructure and data warehouse also offers value-added interactive interfaces to our stakeholders for a superior experience and engagement.

JOCAVIO Co. Ltd. – Second Place
JOCAVIO Co. Ltd. was founded in 2021 by Drs. Tomoko and Hiroyuki Inoue together with seasoned industry experts in 2021 with a vision to provide “Hope for the Irreplaceable Lives of Cancer Patients”. JOCAVIO’s core expertise is genetic manipulation of vaccinia virus and the unique coating technology that enable repeated systemic administration of virus vectors. Moreover, we utilize a promising nanobody technology that allows multi-epitope binding for cancer specific tropism. Our primary focus is a novel oncolytic virus that provides not only robust efficacy with multiple targets but also possesses a “kill switch” that inhibits virus replication in case of excess activity. Utilizing our expertise on vaccinia virus, we have a project on SARS-Cov-2 vaccine that would be effective regardless of different variants. This project is an expedited project in needs of effective vaccines and will enter FIH in 3Q 2023 and we expect to complete P2 in 2024. Similarly, some early pipelines in consideration include vaccines that are effective for Zika and Dengue fever. We are looking for investors to help us in seed finance to support FIH in 2024-2025. Also we are keen on a strategic partnership with companies who are interested in co-development of our vaccine projects in APAC countries.

SynCell Biotechnology, Inc. – Third Place
SynCell’s business is focused on making the cutting edge a reality, offering a pipeline of novel antimicrobial products from our patented platform that improves patients’ quality of life, enhances the quality of care, and reduces the burden on society from the costs of antimicrobial resistance.

Register-now-button-new

RESI-Boston-2022-Banner - new - 1100px

RESI Boston Panels

16 Jun

By Caitlin Dolegowski, Marketing Specialist, LSN

The Redefining Early Stage Investment (RESI) conference series returns in-person to the Westin Copley Place in Boston, MA  September 21-22, with September 23 dedicated to virtual partnering available to in-person and virtual attendees. While the platform for hosting will change, the panels will continue to feature investors, industry experts, and seasoned entrepreneurs providing valuable insight to our conference attendees.

RESI Boston will feature fourteen live panels over two days onsite. The agenda features investor panels (Angels, Family Offices, Corporate Venture Capital) with focus on relevant topics in the life science industry with panels like Oncology Innovation, Medical Devices, Big Pharma, and Digital Health. Life Science Nation’s Tales from the Road panels will also highlight startup founders and entrepreneurs sharing their stories of success along the fundraising journey. This conference will also host panels dedicated to the AI and Longevity sectors, sharing these areas of life science with increasing traction.

As we are transitioning into a hybrid format, these panels will be live and available to view on our live agenda for two weeks after the conference. Register by July 1 to save $500 on super early bird rates.

RESI Boston Preliminary Agenda
Sept. 21 – Wednesday Sept. 22 – Thursday
9 AM EDT Angels
Explaining the Process of Engagement
Digital Health
Leveraging Software, Lowering Costs & Improving Care
10 AM EDT Medical Devices
Investing in Novel Engineering
Big Pharma
Strategies for Preclinical & Early Clinical Assets
11 AM EDT Tales from the Road
The Fundraising Biotech Founder
Tales from the Road
Medtech Startups Redefining Possibility
12 PM EDT Lunch
1 PM EDT Diagnostics
Next-Gen Tech Changing Treatment Paradigms
Corporate VC
The Changing Landscape & New Opportunities
2 PM EDT Tales from the Road
AI at the Intersection of Health and Tech
AI Healthcare Investments
Defining Tech and Discovering Potential
3 PM EDT New, Now, and Next in Longevity Investment
Opportunity and Priorities in Age-Tech
Tales from the Road
Age-Tech Innovators on Their Fundraising Journey
4 PM EDT Family Offices
Perspectives on Seed & Series A Rounds
Oncology Innovation
The Search for New Approaches to Diagnosing & Treating Cancer
5 PM EDT Networking Reception

RESI-Boston-2022-Banner - new - 1100px

The 4 Fs of Successful Meetings

16 Jun

By Rory McCann, Director of Marketing, Conference Producer, LSN

Last week, Life Science Nation (LSN) wrapped up Digital RESI June, its most recent virtual partnering event. As we look ahead to our first in-person partnering conference in over two years, we want to first discuss how to evaluate the success of previous meetings. You’ve done your research, messaged investors, and booked meetings, but after the curtain falls, how do you measure the success of your partnering?

  1. Fit
    1. Was the meeting well-matched between a company and an investor who were matched in product and stage of development?
    2. Did they make any references to existing interest or past investments?
    3. Did they connect you with other peers or colleagues?
  2. Feel
    1. Was the atmosphere pleasant and enjoyable?
    2. Were you confident answering questions and did the potential partner seem equally satisfied?
    3. Is this someone you would enjoy working with more closely?
  3. Follow-Up
    1. Do they want to have a follow-up meeting?
    2. Did they express interest in signing an NDA?
    3. Did they engage you during networking activities and receptions?
  4. Feedback
    1. Did you receive insights on your pitch, technology, or market?
    2. Was the feedback knowledgeable and relevant?
    3. Will it contribute to your future fundraising efforts?

While the success of a meeting isn’t based on an affirmative answer to each question, your honest response to each can help gauge the temperature of your meetings. A negative answer isn’t the definition of failure, either. It’s all data. Coming away from a well-fitting meeting without the feeling that the person or firm is one you’d like to work and spend more time with is valuable and worth further consideration. This is truly what makes successful meetings – not only the quality of the meeting itself but also the valuable information you need to make informed decisions moving forward.

Keep the conversations going and sign up for RESI Boston! Learn more about travel and accommodations and save on super early bird rates!

RESI-Boston-2022-Banner - new - 1100px

SEEDing Biomedical Innovation: Support for Small Businesses at NIH

9 Jun

NIH’s Small Business Program, also known as America’s Seed Fund, provides over $1.2 billion dollars annually to small businesses to validate the healthcare potential of scientific discoveries and test the feasibility of novel products and services. Many companies leverage NIH funding to attract the partners and investors needed to take an innovation to market. This panel will highlight resources and opportunities available to small business innovators looking to support early product development and the ways strategic partners and investors and can partner with NIH to access novel technologies.

Stephanie Fertig, MBA, HHS Small Business Program Lead, Small business Education and Entrepreneurial Development (SEED), National Institutes of Health (NIH)

Fertig is the HHS Small Business Program Lead in SEED (Small business Education and Entrepreneurial Development) at the NIH. She currently oversees the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which are congressionally mandated set-aside programs that provide over $1.2 billion dollars per year to small business concerns. Prior to joining SEED, she managed the SBIR and STTR Programs at the National Institute of Neurological Disorders and Stroke (NINDS). During her tenure at NIH she has led the development and implementation of multiple programs focused on small businesses and translational research.  Ms. Fertig has a BS in Chemistry from UVA and an MBA from the University of Maryland’s Robert H. Smith School of Business.

Loleta Robinson, MD, MBA, Entrepreneur in Residence, Small business Education and Entrepreneurial Development (SEED), National Institutes of Health (NIH); Founder & Principal, Fortis Industries LLC

Dr. Loleta Robinson is a seasoned physician entrepreneur, startup advisor, venture partner with extensive healthcare technology and services expertise. She is the Founder and Principal of Fortis Industries, LLC, a firm specializing in blending data analytics, due diligence, and a strong industry network to identify and evaluate prospective healthcare investment, in-licensing, and partnership opportunities for various clients. Dr. Robinson calls on her extensive industry experience and relationships to help bring together venture capital and corporate innovation firms with healthcare startups and early-stage companies with the potential to significantly improve the quality of care. She also facilitates their collaboration via incubators, accelerators, and other entrepreneurial support organizations and researches the healthcare market landscape to provide competitive analyses and offer industry insights.

For more information, please visit resiconference.com

RESI Boston Returns September 21-23

9 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

More than two years following the last in-person RESI event, Life Science Nation is pleased to announce that RESI returns to an in-person format September 21-22 at the Westin Copley in Boston, MA. September 23 is a day dedicated to digital partnering for virtual and in-person attendees to take advantage of. Since the virtual shift, RESI has navigated the digital world and grown but remains dedicated to its mission: to connect early-stage startups in life science and healthcare with investors and licensing partners who are a fit for their product and stage of development.

The team behind RESI has learned much about what the community looks for in reliable, high-quality partnering, and looks forward to providing invaluable content with convenient and dynamic partnering options, which include both in-person (September 21-22) and virtual (September 23) options. In-person attendees can expect two days of active partnering, interactive panels, educational workshops, and live pitch sessions. Virtual attendees can still benefit from access to content recordings, as well as a single day dedicated exclusively to digital partnering.

We hope you’ll join us and continue to add value to the vibrant RESI community. Registration for RESI Boston is now open! Super early bird rates apply until July 1. Sign up today and save $500!

Register-now-button-new

RESI-Boston-2022-Banner - new - 1100px

Digital RESI June and the Future of Virtual Partnering

9 Jun

By Karen Deyo, Director of Investor Research, Israel BD, LSN

As we reach the end of Digital RESI June, we look forward to RESI Boston and Life Science Nation (LSN)’s first in-person event since January 2020, we are very proud of what we have been able to accomplish in making our virtual events a success. Like all our virtual events, this RESI’s attendees represented LSN’s global ecosystem, with startups and investors from 30 countries and 5 continents. LSN’s offerings have continued to evolve to meet the needs of the early-stage life science ecosystem with the introduction of the Audience Access pass, allowing the earliest stage startups to benefit from the experience and expertise of our investor panels and expert workshops before jumping into their own fundraising campaigns.

While we are all excited to be going back to in person events, the last two years have taught us that virtual partnering is here to stay, and that there will be a new normal for events moving forward. Startups and investors will have the flexibility to decide when they want to make the effort to attend events in person but will still be able to partner multiple times a year even if their schedule will not allow them to travel to every RESI.

We look forward to our next evolution of RESI, and hope that you will join us in person (September 21-22) or virtually (September 23) for RESI Boston!

Register-now-button-new

RESI-Boston-2022-Banner - new - 1100px

Massachusetts Medical Device Development Center (M2D2) Upcoming Events

9 Jun

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Life Science Nation (LSN) is proud to be long-term tech hub partners with the Massachusetts Medical Device Development Center (M2D2). Get involved with M2D2’s upcoming free events geared at setting startups up for success through their IMPACT Accelerator Program. M2D2’s IMPACT Accelerator program is a 12-week accelerator that helps startups bring their technology closer to market.

Learn how to initiate strategic partnerships, valuable networking and more at next Thursday’s M2D2’s CAPCaT Big Company/Little Company Showcase! For the third year in a row, the UMass CAPCaT program will present a high-energy, high-value event highlighting six breakthrough PoCT startups who have utilized CAPCaT funding to advance their solution.

https___cdn.evbuc.com_images_300247419_209363275440_1_original

M2D2 IMPACT logo-transparentTen startups have been working with M2D2 and their Cycle 3 Sponsor Hologic to advance the commercialization of their innovation through the IMPACT Accelerator Program. Join M2D2’s early-stage women’s health medical device startups at the onsite M2D2 IMPACT Accelerator Pitch-Off on July 20. While applications are closed, M2D2 invites all medtech and femtech startups to attend to learn more about the latest innovations in these areas. The Pitch-Off takes place at M2D2 headquarters in Lowell, MA. Meet the finalists and learn more here.

UPDATED-IMPACT-Cycle3-Social

LSN Vice President of Business Development, Candice He will be presenting an award on behalf of the community of early-stage investors, entrepreneurs, and service providers that regularly pitch and participate at RESI partnering events. LSN is pleased to award a premier registration and pitch slot at the upcoming RESI Boston, September 21-22 at Westin Copley, with a third day of dedicated digital partnering on September 23. Originally valued at $2,995, the award includes a 3-day registration with the premier partnering upgrade and a guaranteed spot to pitch at the Innovator’s Pitch Challenge. Sign up for RESI Boston at super early bird rates and get involved with the RESI network today!

RESI-Boston-2022-Banner - new - 1100px